NYSE:NVS - Novartis Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $87.39 -1.01 (-1.14 %) (As of 12/14/2018 04:00 PM ET)Previous Close$87.39Today's Range$87.10 - $87.9152-Week Range$72.30 - $94.19Volume2.46 million shsAverage Volume2.54 million shsMarket Capitalization$204.20 billionP/E Ratio18.17Dividend Yield2.16%Beta0.74 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; and Conatus Pharmaceuticals Inc. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. Receive NVS News and Ratings via Email Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVS Previous Symbol CUSIPN/A Webwww.novartis.com Phone41-61-324-1111 Debt Debt-to-Equity Ratio0.29 Current Ratio1.20 Quick Ratio0.96 Price-To-Earnings Trailing P/E Ratio18.17 Forward P/E Ratio16.74 P/E Growth2.02 Sales & Book Value Annual Sales$49.11 billion Price / Sales4.11 Cash Flow$7.4501 per share Price / Cash Flow11.73 Book Value$32.03 per share Price / Book2.73 Profitability EPS (Most Recent Fiscal Year)$4.81 Net Income$7.70 billion Net Margins25.98% Return on Equity15.81% Return on Assets8.58% Miscellaneous Employees121,597 Outstanding Shares2,310,000,000Market Cap$204.20 billion OptionableOptionable Novartis (NYSE:NVS) Frequently Asked Questions What is Novartis' stock symbol? Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS." How will Novartis' stock buyback program work? Novartis announced that its board has authorized a stock repurchase program on Saturday, April 8th 2017, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.9% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its shares are undervalued. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) released its quarterly earnings data on Thursday, October, 18th. The company reported $1.32 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.31 by $0.01. The business had revenue of $12.78 billion for the quarter, compared to analyst estimates of $12.88 billion. Novartis had a return on equity of 15.81% and a net margin of 25.98%. The business's revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.29 earnings per share. View Novartis' Earnings History. When is Novartis' next earnings date? Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, January 23rd 2019. View Earnings Estimates for Novartis. What price target have analysts set for NVS? 17 analysts have issued twelve-month target prices for Novartis' shares. Their predictions range from $74.71 to $105.00. On average, they anticipate Novartis' share price to reach $89.2467 in the next year. This suggests a possible upside of 2.1% from the stock's current price. View Analyst Price Targets for Novartis. What is the consensus analysts' recommendation for Novartis? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 1 sell rating, 9 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis. Has Novartis been receiving favorable news coverage? News headlines about NVS stock have trended somewhat positive on Saturday, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novartis earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Novartis' key competitors? Some companies that are related to Novartis include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG) and Allergan (AGN). Who are Novartis' key executives? Novartis' management team includes the folowing people: Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)Mr. Harry Kirsch, Chief Financial Officer (Age 53)Mr. Steven Baert, Head of HR (Age 44)Mr. Richard Francis, Chief Exec. Officer of Sandoz (Age 50)Dr. James E. Bradner M.D., Pres of Novartis Institutes for Biomedical Research (Age 46) Who are Novartis' major shareholders? Novartis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Dodge & Cox (1.91%), Primecap Management Co. CA (0.96%), Franklin Resources Inc. (0.65%), Brown Brothers Harriman & Co. (0.32%), Fisher Asset Management LLC (0.32%) and Loomis Sayles & Co. L P (0.32%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis. Which major investors are selling Novartis stock? NVS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Franklin Resources Inc., Brown Brothers Harriman & Co., Deutsche Bank AG, Marshall Wace North America L.P., BlackRock Inc., Manning & Napier Group LLC and Sei Investments Co.. View Insider Buying and Selling for Novartis. Which major investors are buying Novartis stock? NVS stock was bought by a variety of institutional investors in the last quarter, including Matthew Goff Investment Advisor LLC, Point72 Asset Management L.P., Eagle Asset Management Inc., Janus Henderson Group PLC, Bank of New York Mellon Corp, Dodge & Cox, Rockefeller Capital Management L.P. and The Manufacturers Life Insurance Company. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis. How do I buy shares of Novartis? Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novartis' stock price today? One share of NVS stock can currently be purchased for approximately $87.39. How big of a company is Novartis? Novartis has a market capitalization of $204.20 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe. What is Novartis' official website? The official website for Novartis is http://www.novartis.com. How can I contact Novartis? Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected] MarketBeat Community Rating for Novartis (NYSE NVS)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 407 (Vote Outperform)Underperform Votes: 477 (Vote Underperform)Total Votes: 884MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: What is the NASDAQ Stock Market?